Bank of New York Mellon Corp raised its stake in shares of Enzo Biochem Inc. (NYSE:ENZ) by 89.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 187,262 shares of the company’s stock after buying an additional 88,602 shares during the period. Bank of New York Mellon Corp owned about 0.40% of Enzo Biochem worth $1,119,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Raymond James Trust N.A. acquired a new stake in shares of Enzo Biochem during the second quarter valued at about $266,000. Strs Ohio acquired a new stake in shares of Enzo Biochem during the second quarter valued at about $653,000. Goldman Sachs Group Inc. raised its stake in shares of Enzo Biochem by 63.4% in the first quarter. Goldman Sachs Group Inc. now owns 173,561 shares of the company’s stock valued at $790,000 after buying an additional 67,322 shares during the period. Geode Capital Management LLC raised its stake in shares of Enzo Biochem by 3.0% in the first quarter. Geode Capital Management LLC now owns 180,845 shares of the company’s stock valued at $822,000 after buying an additional 5,309 shares during the period. Finally, UBS Group AG raised its stake in shares of Enzo Biochem by 334.7% in the first quarter. UBS Group AG now owns 206,535 shares of the company’s stock valued at $940,000 after buying an additional 159,025 shares during the period. 53.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Enzo Biochem Inc. (NYSE:ENZ) traded up 10.26% on Friday, reaching $5.59. 366,402 shares of the company traded hands. Enzo Biochem Inc. has a one year low of $3.48 and a one year high of $7.00. The firm’s 50 day moving average is $5.34 and its 200 day moving average is $5.68. The company has a market capitalization of $258.62 million, a P/E ratio of 14.63 and a beta of 1.50.
Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings data on Thursday, October 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. The firm had revenue of $26.60 million for the quarter. Enzo Biochem had a negative return on equity of 20.77% and a net margin of 17.27%. During the same quarter in the previous year, the business earned ($0.06) EPS. Analysts expect that Enzo Biochem Inc. will post ($0.23) earnings per share for the current fiscal year.
Separately, Zacks Investment Research downgraded shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th.
About Enzo Biochem
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.